These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 33176070)

  • 1. Sorafenib and CuB exert synergistic antitumor effects against hepatocellular carcinoma cells via inhibition of STAT3 phosphorylation.
    Wang X; Li H; Li D; Bai Y; Zhang Y; Yan X; Li J; Zhao R; Liu J; Liu W; Shi M; Xu C; Yang T; Zhang T
    FEBS Open Bio; 2021 Jan; 11(1):133-145. PubMed ID: 33176070
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cucurbitacin B exhibits antitumor effects on CD133+ HepG2 liver cancer stem cells by inhibiting JAK2/STAT3 signaling pathway.
    Wang X; Bai Y; Yan X; Li J; Lin B; Dai L; Xu C; Li H; Li D; Yang T; Zhang T
    Anticancer Drugs; 2021 Jun; 32(5):548-557. PubMed ID: 33675610
    [TBL] [Abstract][Full Text] [Related]  

  • 3. YC-1 enhances the anti-tumor activity of sorafenib through inhibition of signal transducer and activator of transcription 3 (STAT3) in hepatocellular carcinoma.
    Kong J; Kong F; Gao J; Zhang Q; Dong S; Gu F; Ke S; Pan B; Shen Q; Sun H; Zheng L; Sun W
    Mol Cancer; 2014 Jan; 13():7. PubMed ID: 24418169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic effect of ursodeoxycholic acid on the antitumor activity of sorafenib in hepatocellular carcinoma cells via modulation of STAT3 and ERK.
    Lee S; Cho YY; Cho EJ; Yu SJ; Lee JH; Yoon JH; Kim YJ
    Int J Mol Med; 2018 Nov; 42(5):2551-2559. PubMed ID: 30106087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cucurbitacin E shows synergistic effect with sorafenib by inducing apoptosis in hepatocellular carcinoma cells and regulates Jak/Stat3, ERK/MAPK, PI3K/Akt/mTOR signaling pathways.
    Üremiş MM; Üremiş N; Türköz Y
    Steroids; 2023 Oct; 198():109261. PubMed ID: 37355001
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A combination of sorafenib and SC-43 is a synergistic SHP-1 agonist duo to advance hepatocellular carcinoma therapy.
    Chao TI; Tai WT; Hung MH; Tsai MH; Chen MH; Chang MJ; Shiau CW; Chen KF
    Cancer Lett; 2016 Feb; 371(2):205-13. PubMed ID: 26679051
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sorafenib and its derivative SC-49 sensitize hepatocellular carcinoma cells to CS-1008, a humanized anti-TNFRSF10B (DR5) antibody.
    Chen KF; Chen HL; Shiau CW; Liu CY; Chu PY; Tai WT; Ichikawa K; Chen PJ; Cheng AL
    Br J Pharmacol; 2013 Feb; 168(3):658-72. PubMed ID: 22978563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel STAT3 oligonucleotide compounds suppress tumor growth and overcome the acquired resistance to sorafenib in hepatocellular carcinoma.
    Zhang QY; Ding W; Mo JS; Ou-Yang SM; Lin ZY; Peng KR; Liu GP; Lu JJ; Yue PB; Lei JP; Wang YD; Zhang XL
    Acta Pharmacol Sin; 2024 Aug; 45(8):1701-1714. PubMed ID: 38609562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bazedoxifene exhibits growth suppressive activity by targeting interleukin-6/glycoprotein 130/signal transducer and activator of transcription 3 signaling in hepatocellular carcinoma.
    Ma H; Yan D; Wang Y; Shi W; Liu T; Zhao C; Huo S; Duan J; Tao J; Zhai M; Luo P; Guo J; Tian L; Mageta L; Jou D; Zhang C; Li C; Lin J; Lv J; Li S; Lin L
    Cancer Sci; 2019 Mar; 110(3):950-961. PubMed ID: 30648776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor activity of the microtubule inhibitor MBRI-001 against human hepatocellular carcinoma as monotherapy or in combination with sorafenib.
    Deng M; Li L; Zhao J; Yuan S; Li W
    Cancer Chemother Pharmacol; 2018 May; 81(5):853-862. PubMed ID: 29532153
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel multitarget kinase inhibitor BZG with potent anticancer activity in vitro and vivo enhances efficacy of sorafenib through PI3K pathways in hepatocellular carcinoma cells.
    Wang L; Zhan Y; Wu Z; Lin M; Jin X; Jiang L; Qiu Y
    Biomed Pharmacother; 2020 May; 125():110033. PubMed ID: 32187962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A sorafenib derivative and novel SHP-1 agonist, SC-59, acts synergistically with radiotherapy in hepatocellular carcinoma cells through inhibition of STAT3.
    Huang CY; Tai WT; Hsieh CY; Hsu WM; Lai YJ; Chen LJ; Shiau CW; Chen KF
    Cancer Lett; 2014 Jul; 349(2):136-43. PubMed ID: 24735751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic antitumor activity of sorafenib and artesunate in hepatocellular carcinoma cells.
    Yao X; Zhao CR; Yin H; Wang K; Gao JJ
    Acta Pharmacol Sin; 2020 Dec; 41(12):1609-1620. PubMed ID: 32300243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of STAT3 signaling pathway by ursolic acid suppresses growth of hepatocellular carcinoma.
    Liu T; Ma H; Shi W; Duan J; Wang Y; Zhang C; Li C; Lin J; Li S; Lv J; Lin L
    Int J Oncol; 2017 Aug; 51(2):555-562. PubMed ID: 28714512
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SREBP-1 inhibitor Betulin enhances the antitumor effect of Sorafenib on hepatocellular carcinoma via restricting cellular glycolytic activity.
    Yin F; Feng F; Wang L; Wang X; Li Z; Cao Y
    Cell Death Dis; 2019 Sep; 10(9):672. PubMed ID: 31511501
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GPAT3 is a potential therapeutic target to overcome sorafenib resistance in hepatocellular carcinoma.
    Zhou Y; Zhao H; Ren R; Zhou M; Zhang J; Wu Z; Chen Y; Lei J; Chen Y; Yu Y; Li Y
    Theranostics; 2024; 14(9):3470-3485. PubMed ID: 38948063
    [No Abstract]   [Full Text] [Related]  

  • 17. Sorafenib overcomes TRAIL resistance of hepatocellular carcinoma cells through the inhibition of STAT3.
    Chen KF; Tai WT; Liu TH; Huang HP; Lin YC; Shiau CW; Li PK; Chen PJ; Cheng AL
    Clin Cancer Res; 2010 Nov; 16(21):5189-99. PubMed ID: 20884624
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergistic anticancer activity of 20(S)-Ginsenoside Rg3 and Sorafenib in hepatocellular carcinoma by modulating PTEN/Akt signaling pathway.
    Lu M; Fei Z; Zhang G
    Biomed Pharmacother; 2018 Jan; 97():1282-1288. PubMed ID: 29156516
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Capsaicin and sorafenib combination treatment exerts synergistic anti‑hepatocellular carcinoma activity by suppressing EGFR and PI3K/Akt/mTOR signaling.
    Dai N; Ye R; He Q; Guo P; Chen H; Zhang Q
    Oncol Rep; 2018 Dec; 40(6):3235-3248. PubMed ID: 30272354
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 17β-estradiol exerts anticancer effects in anoikis-resistant hepatocellular carcinoma cell lines by targeting IL-6/STAT3 signaling.
    Lee S; Lee M; Kim JB; Jo A; Cho EJ; Yu SJ; Lee JH; Yoon JH; Kim YJ
    Biochem Biophys Res Commun; 2016 May; 473(4):1247-1254. PubMed ID: 27091428
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.